Cite
HARVARD Citation
Comi, G. et al. (2020). Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple sclerosis. pp. 1866-1876. [Online].